Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 30, Issue 25, 2012, Pages 3084-3092

  Paz Ares, Luis G ^a   Biesma, Bonne ^c   Heigener, David ^e   Von Pawel, Joachim ^f   Eisen, Timothy ^h   Bennouna, Jaafar ^j   Zhang, Li ^l   Liao, Meilin ^m   Sun, Yan ⁿ   Gans, Steven ^d   Syrigos, Kostas ^o   Le Marie, Etienne ^k   Gottfried, Maya ^p   Vansteenkiste, Johan ^q   Alberola, Vincente ^b   Strauss, Uwe Phillip ^g   Montegriffo, Elaine ⁱ   Ong, Teng Jin ^r   Santoro, Armando ^s  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d St Jansdal   (Netherlands)

^e KRANKENHAUS GROSSHANSDORF   (Germany)

^f Asklepios Fachkliniken   (Germany)

^g BAYER PHARMA AG   (Germany)

^h Cambridge Biomedical Research Centre   (United Kingdom)

ⁱ Bayer plc UK   (United Kingdom)

^j CENTRE RENÉ GAUDUCHEAU   (France)

^k Bretonneau Tours   (France)

^l SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^m SHANGHAI CHEST HOSPITAL   (China)

ⁿ CANCER HOSPITAL   (China)

^o UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^p MEIR MEDICAL CENTER   (Israel)

^q UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^r BAYER CORPORATION   (United States)

^s HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; PLACEBO; SORAFENIB;

ABDOMINAL BLEEDING; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BRAIN HEMANGIOMA; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; EPISTAXIS; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LEUKOPENIA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SKIN MANIFESTATION; THROMBOCYTOPENIA; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PLACEBOS; PROTEIN KINASE INHIBITORS; PYRIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865721505     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.7646     Document Type: Article

References (35)

1. Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266, 2009
2. Blanchard EM, Moon J, Hesketh PJ, et al: Comparison of platinum-based chemotherapy in patients older and younger than 70 years: An analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol 6:115-120, 2011
3. Delbaldo C, Michiels S, Rolland E, et al: Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev 4:CD004569, 2007
4. Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 21:3016-3024, 2003
5. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
6. Scagliotti GV, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285-4291, 2002
7. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
8. Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 27:1227-1234, 2009
9. Reck M, von Pawel J, Zatloukal P, et al: Overall survival with cisplatin/gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 21:1804-1809, 2010
10. Wilhelm S, Chien DS: BAY 43-9006: Preclinical data. Curr Pharm Des 8:2255-2257, 2002
11. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004
12. Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858, 2006
13. Adnane L, Trail PA, Taylor I, et al: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407:597-612, 2006
14. Takezawa K, Okamoto I, Yonesaka K, et al: Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res 69:6515-6521, 2009
15. Ulivi P, Arienti C, Amadori D, et al: Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cell lines. J Cell Physiol 220:214-221, 2009
16. Minami H, Kawada K, Ebi H, et al: Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 99:1492-1498, 2008
17. Okamoto I, Miyazaki M, Morinaga R, et al: Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs 28:844-853, 2010
18. Davies JM, Dhruva NS, Walko CM, et al: A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. Lung Cancer 71:151-155, 2011
19. Adjei AA, Molina JR, Mandrekar SJ, et al: Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 13:2684-2691, 2007
20. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al: Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 27:4274-4280, 2009
21. Dy GK, Hillman SL, Rowland KM Jr, et al: A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer 116:5686-5693, 2010
22. Lind JS, Dingemans AM, Groen HJ, et al: A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced nonsmall cell lung cancer. Clin Cancer Res 16:3078-3087, 2010
23. Spigel DR, Burris HA 3rd, Greco FA, et al: Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 29:2582-2589, 2011
24. Gridelli C, Morgillo F, Favaretto A, et al: Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: A randomized phase II study. Ann Oncol 22:1528-1534, 2011
25. Scagliotti G, Novello S, von Pawel J, et al: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835-1842, 2010
26. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
27. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
28. Ulahannan SV, Brahmer JR: Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest 29:325-337, 2011
29. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
30. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
31. Zhou C, Wu Y-L, Chen G, et al: Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. Ann Oncol 21:viii6, 2010 (suppl; abstr LBA13)
32. Gervais R, Rosell R, Vergnenegre A, et al: The EURTAC (European Tarceva vs Chemotherapy) study: Interim results of a phase III randomized trial of erlotinib vs chemotherapy (CT) in advanced non-small-call lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) activating mutation. 14th World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011 (abstr O10.01)
33. Kim ES, Herbst RS, Wistuba II, et al: The BATTLE Trial: Personalizing therapy for lung cancer. Cancer Discov 1:44-53, 2011
34. Smit EF, Dingemans AM, Thunnissen FB, et al: Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: A brief report. J Thorac Oncol 5:719-720, 2010
35. Schiller JH, Lee JW, Hanna NH, et al: A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 26:427s, 2008 (suppl; abstr 8014)